| ANNOVIS BIO INC. DL-,0001 |
| USA |
| Gesundheit |
| US03615A1088 / A2PNH2 |
| 07X (Frankfurt) / ANVS (NYSE) |
| FRA:07X, ETR:07X, 07X:GR, NYSE:ANVS |
| - |
| https://www.annovisbio.co.. |
|
Annovis Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. Its current pipeline centers on oral small-molecule candidates designed to address disorders such as Alzheimer’s disease..
>Volltext.. |
| 44.39 Mio. EUR |
| 27.96 Mio. EUR |
| - |
| -43.29 Mio. EUR |
| -43.29 Mio. EUR |
| -1.57 EUR |
| - |
| 16.37 Mio. EUR |
| -37.88 Mio. EUR |
| 2.95 |
| - |
| -68.81% |
| - |
| - |
| - |
| - |
| ANNOVIS BIO |
| 23.09.26 |
|